AUTHOR=Szewczyk Katarzyna , Wieczorek Aleksandra , Młynarski Wojciech , Janczar Szymon , Woszczyk Mariola , Gamrot Zuzanna , Chaber Radosław , Wysocki Mariusz , Pogorzała Monika , Bik-Multanowski Mirosław , Balwierz Walentyna 

TITLE=Unfavorable Outcome of Neuroblastoma in Patients With 2p Gain

JOURNAL=Frontiers in Oncology

VOLUME=9

YEAR=2019

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2019.01018

DOI=10.3389/fonc.2019.01018

ISSN=2234-943X

ABSTRACT=<p><bold>Background:</bold> Amplification of the <italic>MYCN</italic> oncogene is the most unfavorable genetic factor in neuroblastoma patients. However, knowledge about the clinical impact of low-level multiplication of <italic>MYCN</italic> is still insufficient. Therefore, we aimed to investigate the disease course in patients with different copy number status of <italic>MYCN</italic>.</p><p><bold>Materials and Methods:</bold> We examined 105 children diagnosed with neuroblastoma from 2010 to 2018 in five pediatric oncology centers in Poland. We determined the <italic>MYCN</italic> status at diagnosis by the interphase FISH examination and assessed the clinical outcome in patients.</p><p><bold>Results:</bold> A total of 35% of tumors presented with chromosome 2 numerical changes, 20% had <italic>MYCN</italic> amplification and 16% revealed 2p gain. Unexpectedly, we observed very low overall survival and event free survival (EFS) rates in neuroblastomas with 2p gain, which were comparable with patients with <italic>MYCN</italic> amplification.</p><p><bold>Conclusions:</bold> The 2p gain alteration should be reported as a strong unfavorable prognostic marker in neuroblastoma patients.</p>